Kyle Bass Should Be Ashamed, But He Doesn’t Seem To Be


Tricksters have a nebulous way about them, and likely they rationalize away their misdeeds with reams of anti-logic that is schizophrenic in its depth and inconsistency. Though to the trickster, it is entirely consistent. This must, in some way, be how Bass functions. He appears to evince sincerity on his mainstream media appearances, but his actions are so tangent to this sincerity that they paint the man an Oscar-worthy actor or a lunatic.

For readers unaware, Kyle Bass was unknown until 2008, when he successfully predicted sub-prime lending practices in America would result in an economic implosion. His prediction was borne out by reality, and as a result virtually overnight he became a vetted financier on the mainstream media stage. Since then, the hedge fund he manages out of Texas has performed poor in a way that seems to reflect a continual trend related to his media appearances, and his relationship to Cristina Fernandez de Kirchner has made some major waves.

Cristina Fernandez de Kirchner is a despotic socialist leader of Argentina, poorly presiding over the country in a way that is historically memorable. She made a record! She defaulted Argentina twice in the span of thirteen years. Despite this, Bass has nothing but good things to say about the woman, and says them regularly on the national stage. Is this insanity, or cunning? Well, in either case, the proper shame following such incorrect statements doesn’t seem to follow Bass.

Where he should be most ashamed is in his leadership of the organization CAD, which has managed to make Bass millions through stock he short-sold after he manipulated the stock market. CAD stands for the Coalition for Affordable Drugs, and the purpose of the group is to stir up human rights activists and impoverished infirm people such that petitions are signed and lawsuits are filed against big-ticket pharmaceutical organizations. These organizations medications are then sold for an exceptionally reduced rate–sometimes to the tune of ninety-percent reduction, in point of fact–and the big-ticket biotech companies lose so much money, many cases they’re forced to axe funding to departments like R&D (Research and Development). In the end, future cures and breakthroughs are either halted or delayed, ensuring those who could benefit from them will have a diminished chance of recovery.

Kyle Bass isn’t ashamed, though. In fact, he supports his actions with CAD, Kirchner, and his hedge fund. The man either has ulterior motives, he’s insane, or he’s bumbled into his current position in some way reminiscent of inspector Jacques Clouseau.